CAMBRIDGE, Mass.—NinePoint Medical, Inc., a company that develops medical devices for in vivo pathology, this month announced that the company will preview its next-generation optical imaging technology, the NvisionVLE™ Imaging System, at Digestive Disease Week 2012 (DDW 2012), being held this week in San Diego.
NinePoint Medical will provide public demonstrations of the NvisionVLE Imaging System, which is designed to bridge the gap between diagnosis and disease treatment by enabling physicians and pathologists to evaluate high-resolution, volumetric images of organs and tissues in real time.
“We are looking forward to providing DDW 2012 attendees with informative and interactive demonstrations of our proprietary NvisionVLE Imaging System," said Charles Carignan, MD, president and chief executive officer of NinePoint Medical. “The NvisionVLE Imaging System is designed to provide real-time images that will enable physicians to visually assess diseased tissues deeper than is possible with endoscopy, the current standard of care. We’re continuing to make important progress and this has been an exciting year for us, with 510(k) clearance from the FDA and the initiation of our multi-center clinical trial for the evaluation of Barrett’s esophagus."
The NvisionVLE Imaging System is the first volumetric, optical coherence tomography (OCT) device cleared by the U.S. Food and Drug Administration (FDA) for endoscopic imaging that generates cross sectional and longitudinal images simultaneously, in real time. Unlike traditional imaging devices that image only the surface of organs and tissues, NinePointMedical’s proprietary technology enables the generation of images up to 3mm deep and at better than 10-micron resolution.
NinePoint Medical recently initiated a clinical trial to evaluate high-resolution optical imaging of Barrett’s esophagus using the NvisionVLE Imaging System. Barrett’s esophagus is one of the most common precursors to esophageal cancer, which is ranked among the top 10 causes of cancer-related deaths worldwide.
In January 2012, the company announced 510(k) clearance from the FDA to market its NvisionVLE Imaging System for use as an imaging tool in the evaluation of human tissue microstructure by providing two-dimensional, cross sectional, real-time depth visualization. Based on the rapid and significant progress made in the development of the NvisionVLE Imaging System this year, NinePoint Medical remains on track for a commercial launch of the System in 2013.
